SpaceX, Palantir, AMD, Marvell, Caterpillar, Pfizer, and More Stocks That Explain Today's Market

Dow Jones00:59

Stocks advanced on Tuesday with the S&P 500 and the Dow Jones Industrial Average setting record highs intraday as tech names marched higher and chip stocks reemerged as a key market driver.

SpaceX rose 6%. After the market closes, attention will be on Elon Musk's AI and rocket company, which reports its inaugural quarterly numbers. Wall Street projects sales of $6.8 billion and earnings before interest, taxes, depreciation, and amortization, or Ebitda, of $2.1 billion.

The artificial-intelligence trade made a strong comeback after Reuters reported the U.S. plans to ban imports of new China-made data-center parts. Coherent and Lumentum gained 15% and 9.5%, respectively. Corning was up 9.5% while Marvell gained 14% and Micron rose 8.4%.

Advanced Micro Devices advanced 8.2%. The chip company is scheduled to report second-quarter earnings after the close of trading on the heels of a rout of chip stocks in July that had corrected a fierce spring rally.

SK Hynix rose 6.2% to $151.61. William Blair initiated coverage of the South Korean chip maker's U.S. listing with an Outperform rating and a $260 price target. That price target represents 82% upside from Monday's closing price.

Sandisk gained 11%. SK Hynix and Sandisk announced the release of a technical blueprint for their high bandwidth flash technology on Tuesday.

Palantir surged 29%, leading the S&P 500, after the data analytics software developer reported strong second-quarter earnings. CEO Alex Karp described the quarter as "otherworldly," as U.S. commercial revenue rose 149% from a year ago.

Caterpillar added 6.7% after the industrial machinery maker smashed Wall Street's second-quarter earnings estimates.

Merck rose 1.5%. The company topped analysts' second-quarter targets across its top and bottom lines even as dealmaking costs from a recent acquisition weighed on results. Merck's quarterly beat was driven by the continued adoption of Keytruda, the company's blockbuster cancer treatment.

Pfizer advanced 1.9% after the drugmaker lifted the bottom end of its full-year revenue guidance, citing growth in its non-Covid pharmaceutical portfolio. The company's second-quarter results also came in above Wall Street's expectations.

Moderna gained 4.4%. The drugmaker said it had vaccinated the first participants in an early-stage clinical trial evaluating the safety of its ebola vaccine candidate, mRNA-1469. Moderna's vaccine targets Bundibugyo ebolavirus (BDBV). The update comes as a BDBV outbreak spreads through the Democratic Republic of the Congo.

Wayfair soared 31% after the furniture retailer reported better-than-expected second-quarter earnings, with sequential revenue growth at its best level since 2020.

Zebra Technologies advanced 23%. The automation technology provider's second-quarter numbers handily beat Wall Street expectations. For the full year, Zebra expects sales growth of about 15%, up from prior guidance of 12%.

Fellow automation technology provider Rockwell Automation declined 7.8% even as the company reported better-than-expected fiscal third-quarter earnings and raised its full-year guidance.

Aptiv sank 17% and was the worst-performing stock in the S&P 500. The provider of software and hardware for automotive safety and self-driving applications reported better-than-expected second-quarter profit but guidance was a problem with Wall Street wanting more from both the third quarter and the full year view.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment